Trials / Unknown
UnknownNCT04610970
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
A Single-arm, Open-label, Multicenter, Phase II Clinical Trials of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapse/refactory diffuse large B-cell lymphoma who have received at least 2 lines of therapeutic schedules including rituximab. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3525 tablets | TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle. |
Timeline
- Start date
- 2021-01-20
- Primary completion
- 2022-03-31
- Completion
- 2022-06-30
- First posted
- 2020-11-02
- Last updated
- 2021-08-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04610970. Inclusion in this directory is not an endorsement.